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arthroscopy of the knee has revolutionised the care of patients with meniscal lesions, ruptures of the anterior cruciate ligament, and cartilage damage. Although knee arthroscopy has proved to be an asset that is highly beneficial to many patients, it is not a panacea for all knee problems. The clinical benefit is especially questionable for patients with degenerative osteoarthritis: in a trial using a sham surgery, 2 knee arthroscopy had no effect, and this finding was confirmed in another study. 3 The difficulty of implanting evidence-based surgery in daily surgical practice is highlighted by the large number of patients who still have arthroscopy in osteoarthritic knees. 4 The possibility of arthroscopy in joints other than the knee has also been explored. Shoulder arthroscopy has been taken up widely, 5,6 although indications are not clearly defined. Two areas that are possibly indicated are the glenohumeral joint for intra-articular lesions and the subacromial area that is extra-articular. An impingement syndrome of the subacromial area is responsible for up to 70% of all shoulder problems.
7 This impingement arises due to the restricted space between the acromion and the glenohumeral head, where rotator cuff tendons slice back and forth in abduction and ante version, facilitated by a subacromial bursa. An impingement of these rotator cuff tendons occurs frequently in patients older than 40 years, with typical complaints such as a painful arc. 8 To overcome this impingement problem, in 1972 Neer 8 proposed open decompression of this area, removing osseous spurs from the caudal side of the acromion, often combined with release of the coracoacromial ligament and a bursectomy. An arthroscopic version of this popular procedure was developed and is now frequently undertaken, with an increase of nearly ten times in England from 2500 surgeries in 2000 to 21 000 in 2010. 6 However, as correctly pointed out in The Lancet by David Beard and colleagues 9 for the Can Shoulder Arthroscopy Work (CSAW) study group, the scientific clinical evidence in favour of this type of shoulder surgery is scarce. In Beard and colleagues' multicentre, pragmatic, parallel group, placebo-controlled, threegroup, randomised surgical trial, 106 patients were assigned to decompression surgery, 103 to arthroscopy only, and 104 to no treatment. The primary outcome was the Oxford Shoulder Score at 6 months, analysed by intention to treat.
9
The study group should be commended for undertaking this difficult trial. Two factors that made an assessment of effect difficult were the rather high level of non-compliance in the groups (24 [23%], 43 [42%], and 12 [12%] of the decompression, arthroscopy only, and no-treatment groups, respectively, did not receive their assigned treatment, making the groups more similar and thus differences harder to detect) and the long waiting list, with a waiting time of up to 4 months considered to be acceptable. Thus, patients who were only 2 months post surgery were compared with patients who were 6 months into the no-treatment option. However, the outcome was still remarkable. There was no difference in the primary outcome between the arthroscopic decompression and arthroscopy only groups (decompression mean 32·7 points [SD 11·6] vs arthroscopy mean 34·2 points [9·2]; mean difference -1·3 points [95% CI -3·9 to 1·3], p=0·3141). This is an intriguing finding, showing that subacromial decompression does not affect the clinical outcome.
Additionally, although patients in the surgical groups had statistically better outcomes than the no-treatment group, the differences were small and not clinically important. Although the sizes of the differences are difficult to interpret because of the high non-compliance levels and long waiting list, the differences themselves might be attributed to the placebo effect after surgery. 
